Unicycive Therapeutics, Inc. (UNCY)
| Market Cap | 103.02M -16.9% |
| Revenue (ttm) | n/a |
| Net Income | -36.21M |
| EPS | -1.44 |
| Shares Out | 29.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 886,066 |
| Open | 3.560 |
| Previous Close | 3.570 |
| Day's Range | 3.420 - 3.650 |
| 52-Week Range | 3.330 - 8.740 |
| Beta | 1.87 |
| Analysts | Strong Buy |
| Price Target | 26.30 (+645.04%) |
| Earnings Date | Nov 16, 2026 |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $26.3, which is an increase of 645.04% from the latest price.
News
Unicycive Therapeutics reports Q3 EPS (33c), consensus (35c)
“We believe that the FDA’s acceptance of our NDA resubmission for OLC marks an important step toward our goal of bringing this much-needed treatment to patients,” said Shalabh Gupta, CEO…
Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
MOUNTAIN VIEW, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidn...
Unicycive Therapeutics Quarterly report: Q3 2026
Unicycive Therapeutics has published its Q3 2026 quarterly earnings report on November 16, 2026.
Unicycive Therapeutics Earnings release: Q3 2026
Unicycive Therapeutics released its Q3 2026 earnings on November 16, 2026, summarizing the period's financial results.
Unicycive Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
OLC targets the unmet need for phosphate control with a small, swallowable pill; the FDA action date is March 25, 2027. Launch preparations are underway, with TDAPA reimbursement expected from October 1, 2027, assuming approval and designation.
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidn...
Unicycive Therapeutics Slides: Corporate presentation
Unicycive Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 2, 2026.
Kaplan Fox Alerts Investors: Lead Plaintiff Deadline for Unicycive Therapeutics, Inc. (UNCY) is November 2, 2026
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Com...
What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G.
Suit alleges Unicycive Therapeutics, Inc. failed to disclose key facts to investors from December 29, 2025 through June 29, 2026; lead plaintiff deadline is November 2, 2026 BENSALEM TOWNSHIP, Pa., Oc...
What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R.
Lawsuit alleges Unicycive Therapeutics, Inc. made misleading statements to investors from December 29, 2025 to June 29, 2026; lead plaintiff motions are due November 2, 2026 LOS ANGELES, Oct. 21, 2026...
Unicycive Therapeutics announces FDA acceptance of resubmission of OLC NDA
Unicycive Therapeutics (UNCY) announced that the FDA has accepted the resubmission of its new drug application, or NDA, for oxylanthanum carbonate, or OLC, the company’s investigational oral phosphate...
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pat...
Kaplan Fox Urges Investors of Unicycive Therapeutics, Inc. (UNCY) to Seek a Leadership Role Before November 2, 2026
New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Com...
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Com...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY
Unicycive's annual report warned only that the FDA "could ask us to supplement our submissions," while a securities class action alleges the Company never disclosed that it had not inspected the third...
Kaplan Fox Reminds Unicycive Therapeutics, Inc. (UNCY) Investors to Seek a Leadership Role Before Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Comp...
Unicycive Therapeutics appoints Manning to its Board of Directors
Unicycive Therapeutics (UNCY) announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Most recently, she served as Chief Commercial Officer of Soleno Therapeutics (SLNO) Publ...
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pat...
Kaplan Fox Notifies Investors of Unicycive Therapeutics, Inc. (UNCY) of the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "C...
Unicycive Therapeutics price target lowered to $13 from $15 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $13 from $15 and keeps a Buy rating on the shares after the company announced that it resubmitted…
Unicycive Therapeutics announces resubmission of NDA for OLC
Unicycive Therapeutics (UNCY) announced the resubmission of its New Drug Application, NDA, for oxylanthanum carbonate, OLC, the Company’s investigational oral phosphate binder for the treatment of hyp...
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for pa...
Kaplan Fox Advises Unicycive Therapeutics, Inc. (UNCY) Investors to Act Before the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "C...
UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acqui...
Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies
San Diego, California--(Newsfile Corp. - September 15, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...